Advertisement

Ambulatory Blood Pressure and Adherence Monitoring: Diagnosing Pseudoresistant Hypertension

      Summary

      A small proportion of the treated hypertensive population consistently has a blood pressure greater than 140/90 mm Hg despite a triple therapy including a diuretic, a calcium channel blocker, and a blocker of the renin-angiotensin system. According to guidelines, these patients have so-called resistant hypertension. The prevalence of this clinical condition is higher in tertiary than primary care centers and often is associated with chronic kidney disease, diabetes, obesity, and sleep apnea syndrome. Exclusion of pseudoresistant hypertension using ambulatory or home blood pressure monitoring is a crucial step in the investigation of patients with resistant hypertension. Thus, among the multiple factors to consider when investigating patients with resistant hypertension, ambulatory blood pressure monitoring should be performed very early. Among other factors to consider, physicians should investigate patient adherence to therapy, assess the adequacy of treatment, exclude interfering factors, and, finally, look for secondary forms of hypertension. Poor adherence to therapy accounts for 30% to 50% of cases of resistance to therapy depending on the methodology used to diagnose adherence problems. This review discusses the clinical factors implicated in the pathogenesis of resistant hypertension with a particular emphasis on pseudoresistance, drug adherence, and the use of ambulatory blood pressure monitoring for the diagnosis and management of resistant hypertension.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mancia G.
        • De Backer G.
        • Dominiczak A.
        • Cifkova R.
        • Fagard R.
        • Germano G.
        • et al.
        ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.
        J Hypertens. 2007; 25: 1751-1762
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • Cushman W.C.
        • Dennison-Himmelfarb C.
        • Handler J.
        • et al.
        2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        JAMA. 2014; 311: 507-520
        • Joffres M.
        • Falaschetti E.
        • Gillespie C.
        • Robitaille C.
        • Loustalot F.
        • Poulter N.
        • et al.
        Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study.
        BMJ Open. 2013; 3: e003423
        • Acelajado M.C.
        • Pisoni R.
        • Dudenbostel T.
        • Dell’Italia L.J.
        • Cartmill F.
        • Zhang B.
        • et al.
        Refractory hypertension: definition, prevalence, and patient characteristics.
        J Clin Hypertens. 2012; 14: 7-12
        • Cushman W.C.
        • Ford C.E.
        • Cutler J.A.
        • Margolis K.L.
        • Davis B.R.
        • Grimm R.H.
        • et al.
        • for the ALLHAT Collaborative Research Group
        Success and predictors of BP control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT).
        J Clin Hypertens. 2002; 4: 393-404
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • Goff D.C.
        • Murphy T.P.
        • Toto R.D.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Hypertension. 2008; 51: 1403-1419
        • Persell S.D.
        Prevalence of resistant hypertension in the United States, 2003–2008.
        Hypertension. 2011; 57: 1076-1080
        • Egan B.M.
        • Zhao Y.
        • Axon R.N.
        • Brzezinski W.A.
        • Ferdinand K.D.
        Uncontrolled and apparent treatment resistant hypertension in the U.S. 1988–2008.
        Circulation. 2011; 124: 1046-1058
        • de la Sierra A.
        • Segura J.
        • Banegas J.R.
        • Gorostidi M.
        • de la Cruz J.J.
        • Armario P.
        • et al.
        Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.
        Hypertension. 2011; 57: 898-902
        • Calhoun D.A.
        • Booth 3rd, J.N.
        • Oparil S.
        • Irvin M.R.
        • Shimbo D.
        • Lackland D.T.
        • et al.
        Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.
        Hypertension. 2014; 63: 451-458
        • Daugherty S.L.
        • Powers J.D.
        • Magid D.J.
        • Tavel H.M.
        • Masoudi F.A.
        • Margolis K.L.
        • et al.
        Incidence and prognosis of resistant hypertension in hypertensive patients.
        Circulation. 2012; 125: 1635-1642
        • Gupta A.K.
        • Nasothimiou E.G.
        • Chang C.L.
        • Sever P.S.
        • Dahlöf B.
        • Poulter N.R.
        • ASCOT Investigators
        Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
        J Hypertens. 2011; 29: 2004-2013
        • O׳Brien E.
        • Parati G.
        • Stergiou G.
        Ambulatory blood pressure measurement: what is the international consensus?.
        Hypertension. 2013; 62: 988-994
        • Waeber B.
        • Scherrer U.
        • Petrillo A.
        • Bidiville J.
        • Nussberger J.
        • Waeber G.
        • et al.
        Are some hypertensive patients overtreated? A prospective study of ambulatory blood pressure recording.
        Lancet. 1987; 2: 732-734
        • Krause T.
        • Lovibond K.
        • Caulfield M.
        • McCormack T.
        • Williams B.
        • Guideline Development Group
        Management of hypertension: summary of NICE guidance.
        BMJ. 2011; 343: d4891
        • Bobrie G.
        • Chatellier G.
        • Genes N.
        • Clerson P.
        • Vaur L.
        • Vaisse B.
        • et al.
        Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients.
        JAMA. 2004; 291: 1342-1349
        • Pogue V.
        • Rahman M.
        • Lipkowitz M.
        • Toto R.
        • Miller E.
        • Faulkner M.
        • et al.
        • African American Study of Kidney Disease and Hypertension Collaborative Research Group
        Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease.
        Hypertension. 2009; 53: 20-27
        • Yano Y.
        • Bakris G.L.
        Recognition and management of masked hypertension: a review and novel approach.
        J Am Soc Hypertens. 2013; 7: 244-252
        • Franklin S.S.
        • Thijs L.
        • Li Y.
        • et al.
        International Database on Ambulatory blood pressure in Relation to Cardiovascular Outcomes Investigators. Masked hypertension in diabetes mellitus: treatment implications for clinical practice.
        Hypertension. 2013; 61: 964-971
        • Clinical implications
        Masked hypertension in diabetes mellitus.
        Hypertension. 2013; 61: 931
        • Ríos M.T.
        • Domínguez-Sardiña M.
        • Ayala D.E.
        • Gomara S.
        • Sineiro E.
        • Pousa L.
        • et al.
        Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring.
        Chronobiol Int. 2013; 30: 207-220
        • De Nicola L.
        • Gabbai F.B.
        • Agarwal R.
        • Chiodini P.
        • Borrelli S.
        • Bellizzi V.
        • et al.
        Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients.
        J Am Coll Cardiol. 2013; 61: 2461-2467
        • Burnier M.
        • Wuerzner G.
        • Struijker Boudier H.
        • Urquhart J.
        Measuring, analyzing and managing drug adherence in resistant hypertension.
        Hypertension. 2013; 62: 218-225
        • Naderi S.H.
        • Bestwick J.P.
        • Wald D.S.
        Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
        Am J Med. 2012; 125: 882-887
        • Vrijens B.
        • Vincze G.
        • Kristanto P.
        • Urquhart J.
        • Burnier M.
        Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.
        BMJ. 2008; 336: 1114-1117
        • Shi L.
        • Liu J.
        • Koleva Y.
        • Fonseca V.
        • Kalsekar A.
        • Pawaskar M.
        Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices.
        Pharmacoeconomics. 2010; 28: 1097-1107
        • Hamilton G.A.
        Measuring adherence in a hypertension clinical trial.
        Eur J Cardiovasc Nurs. 2003; 2: 219-228
        • Burnier M.
        • Schneider M.P.
        • Chioléro A.
        • Stubi C.L.
        • Brunner H.R.
        Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions.
        J Hypertens. 2001; 19: 335-341
        • Daugherty S.L.
        • Powers J.D.
        • Magid D.J.
        • Masoudi F.A.
        • Margolis K.L.
        • O׳Connor P.J.
        • et al.
        The association between medication adherence and treatment intensification with BP control in resistant hypertension.
        Hypertension. 2012; 60: 303-309
        • Jung O.
        • Gechter J.L.
        • Wunder C.
        • Paulke A.
        • Bartel C.
        • Geiger H.
        • et al.
        Resistant hypertension? Assessment of adherence by toxicological urine analysis.
        J Hypertens. 2013; 31: 766-774
        • Morisky D.E.
        • Green L.W.
        • Levine D.M.
        Concurrent and predictive validity of a self-reported measure of medication adherence.
        Med Care. 1986; 24: 69-74
        • Pimenta E.
        • Gaddam K.K.
        • Oparil S.
        • Aban I.
        • Husain S.
        • Dell׳Italia L.J.
        • et al.
        Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.
        Hypertension. 2009; 54: 475-481
        • Iftikhar I.H.
        • Hays E.R.
        • Iverson M.A.
        • Magalang U.J.
        • Maas A.K.
        Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis.
        J Clin Sleep Med. 2013; 9: 165-174
        • Martínez-García M.A.
        • Capote F.
        • Campos-Rodríguez F.
        • Lloberes P.
        • Díaz de Atauri M.J.
        • Somoza M.
        • et al.
        Spanish Sleep Network. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial.
        JAMA. 2013; 310: 2407-2415
        • Yakovlevitch M.
        • Black H.R.
        Resistant hypertension in a tertiary care clinic.
        Arch Intern Med. 1991; 151: 1786-1792
        • Setaro J.F.
        • Black H.R.
        Refractory hypertension.
        N Engl J Med. 1992; 327: 543-547
        • Egan B.M.
        • Zhao Y.
        • Li J.
        • Brzezinski W.A.
        • Todoran T.M.
        • Brook R.D.
        • et al.
        Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.
        Hypertension. 2013; 62: 691-697
        • Peterzan M.A.
        • Hardy R.
        • Chaturvedi N.
        • Hughes A.D.
        Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.
        Hypertension. 2012; 59: 1104-1109
        • Roush G.C.
        • Holford T.R.
        • Guddati A.K.
        Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.
        Hypertension. 2012; 59: 1110-1117
        • Ernst M.E.
        • Carter B.L.
        • Goerdt C.J.
        • Steffensmeier J.J.
        • Phillips B.B.
        • Zimmerman M.B.
        • et al.
        Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
        Hypertension. 2006; 47: 352-358
        • Na K.Y.
        • Oh Y.K.
        • Han J.S.
        • Lee J.S.
        • Earm J.H.
        • Knepper M.A.
        • et al.
        Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats.
        Am J Physiol Renal Physiol. 2003; 284: F133-F143
        • Nielsen J.
        • Kwon T.H.
        • Masilamani S.
        • Beutler K.
        • Hager H.
        • Nielsen S.
        • et al.
        Sodium transporter abundance profiling in kidney: effect of spironolactone.
        Am J Physiol Renal Physiol. 2002; 283: F923-F933
        • Knauf H.
        • Mutschler E.
        Sequential nephron blockade breaks resistance to diuretics in edematous states.
        J Cardiovasc Pharmacol. 1997; 29: 367-372
        • Bobrie G.
        • Frank M.
        • Azizi M.
        • Peyrard S.
        • Boutouyrie P.
        • Chatellier G.
        • et al.
        Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
        J Hypertens. 2012; 30: 1656-1664
        • Gaddam K.K.
        • Nishizaka M.K.
        • Pratt-Ubunama M.N.
        • Pimenta E.
        • Aban I.
        • Oparil S.
        • et al.
        Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.
        Arch Intern Med. 2008; 168: 1159-1164
        • Chapman N.
        • Dobson J.
        • Wilson S.
        • Dahlöf B.
        • Sever P.S.
        • Wedel H.
        • et al.
        Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension.
        Hypertension. 2007; 49: 839-845
        • Engbaek M.
        • Hjerrild M.
        • Hallas J.
        • Jacobsen I.A.
        The effect of low-dose spironolactone on resistant hypertension.
        J Am Soc Hypertens. 2010; 4: 290-294
        • Alvarez-Alvarez B.
        • Abad-Cardiel M.
        • Fernandez-Cruz A.
        • Martell-Claros N.
        Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system.
        J Hypertens. 2010; 28: 2329-2335
        • Ouzan J.
        • Perault C.
        • Lincoff A.M.
        • Carre E.
        • Mertes M.
        The role of spironolactone in the treatment of patients with refractory hypertension.
        Am J Hypertens. 2002; 15: 333-339
        • Nishizaka M.K.
        • Zaman M.A.
        • Calhoun D.A.
        Efficacy of low-dose spironolactone in subjects with resistant hypertension.
        Am J Hypertens. 2003; 16: 925-930
        • Sharabi Y.
        • Adler E.
        • Shamis A.
        • Nussinovitch N.
        • Markovitz A.
        • Grossman E.
        Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
        Am J Hypertens. 2006; 19: 750-755
        • Lane D.A.
        • Shah S.
        • Beevers D.G.
        Low-dose spironolactone in the management of resistant hypertension: a surveillance study.
        J Hypertens. 2007; 25: 891-894
        • de Souza F.
        • Muxfeldt E.
        • Fiszman R.
        • Salles G.
        Efficacy of spironolactone therapy in patients with true resistant hypertension.
        Hypertension. 2010; 55: 147-152
        • Gaddam K.
        • Pimenta E.
        • Thomas S.J.
        • Cofield S.S.
        • Oparil S.
        • Harding S.M.
        • et al.
        Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
        J Hum Hypertens. 2010; 24: 532-537
        • Václavík J.
        • Sedlák R.
        • Plachy M.
        • Navrátil K.
        • Plásek J.
        • Jarkovsky J.
        • et al.
        Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
        Hypertension. 2011; 57: 1069-1075
        • Bakris G.L.
        • Nadim M.K.
        • Haller H.
        • Lovett E.G.
        • Schafer J.E.
        • Bisognano J.D.
        Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
        J Am Soc Hypertens. 2012; 6: 152-158
        • Mahfoud F.
        • Ukena C.
        • Schmieder R.E.
        • Cremers B.
        • Rump L.C.
        • et al.
        Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
        Circulation. 2013; 128: 132-140
        • Persu A.
        • Jin Y.
        • Azizi M.
        • Baelen M.
        • Volz S.
        • Elvan A.
        • et al.
        Blood pressure changes after renal denervation at 10 European expert centers.
        J Hum Hypertens. 2013; 12: 868-879